IDXX Stock Analysis: Buy, Sell, or Hold?
IDXX - Idexx Laboratories Inc
$556.93
11.07 (2.03%)
â˛
5d:
+1.08%
30d:
+3.26%
90d:
+0.7%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When IDXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IDXX is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IDXX is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$625.08
Based on 8.4% avg growth
INTRINSIC VALUE TODAY
$388.13
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IDXX is currently trading at $556.93, which is considered fair relative to its 30-day fair value range of $548.12 to $579.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 33.3) compared to its historical average (38.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 17.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IDXX is showing sideways momentum. Immediate support is located at $538.20, while resistance sits at $602.00.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $698.92 (+25.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IDXX is showing sideways momentum. Immediate support is located at $538.20, while resistance sits at $602.00.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $698.92 (+25.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$548.12 -
$579.62
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
Protect Your Profits
Holding IDXX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.5% below Wall St target ($698.92)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$548.12 -
$579.62
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$20.99
(3.8%)
Support & Resistance Levels
Support Level
$538.20
Resistance Level
$602.00
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.27
Wall Street Target
$698.92
(+25.5%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
17.6%
Profit Margin
25.0%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
33.3 vs 38.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$532.43
(-4%)
2-Year Target
$509.00
(-9%)
3-Year Target
$486.60
(-13%)
3-Yr Target (if PE normalizes)
(PE: 33â38)
$557.25
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.3, Growth: 12.8%)
$800.17
(+44%)
Base:
(SPY PE: 20.1, Growth: 12.8%)
$482.70
(-13%)
Bear:
(PE: 17.1, Growth: 12.8%)
$410.29
(-26%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (33x PE) as earnings recover.
Trailing PE: 39.53 | Current EPS (TTM): $13.81
Bull Case
$727.83
(+31%)
Analyst growth 21.2%, PE expands to 43.5
Base Case
$661.66
(+19%)
Market implied 21.2%, PE stable at 39.5
Bear Case
$371.18
(-33%)
Severe decline -20.0%, PE contracts to 33.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 33.3 to 38.1
Stabilization Target:
$637.78
(+14.5%)
PE Expansion Potential:
+14.5%
Share & Embed Analysis
Last updated: August 22, 2026 11:50 AM ET
Data refreshes hourly during market hours. Next update: 12:50 PM
Data refreshes hourly during market hours. Next update: 12:50 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IDXX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
Nimrata Hunt
SELL
1758 shares
2026-03-03
Jonathan Jay Mazelsky
SELL
23326 shares
2026-02-26
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 50 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 43 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
Advanced IDXX Option Strategies
Professional options setups generated by AI based on today's IDXX price and gamma walls.
